Hemovigilance Systems and Post-Transfusion Complication Surveillance

Hemovigilance is the organized, ongoing surveillance of adverse events and reactions across the transfusion chain, from blood donation to recipient outcome. By systematically collecting and analyzing reports of transfusion reactions, near-misses, and errors, hemovigilance systems quantify the residual hazards of transfusion and provide the evidence base for safety improvements. It is the transfusion-medicine counterpart to pharmacovigilance for medicines.

Definition

Hemovigilance is a set of surveillance procedures covering the whole transfusion chain, intended to collect and assess information on unexpected or undesirable effects of blood transfusion and to prevent their occurrence or recurrence.

Scope

This entry covers the concept and purpose of hemovigilance, the kinds of events captured (reactions, near-misses, and process errors), national and international reporting frameworks, and how aggregated data inform transfusion safety. It treats hemovigilance as a surveillance discipline and reference subject, not as operational reporting instructions.

Key concepts

• Surveillance across the transfusion chain
• Adverse reaction and adverse event reporting
• Near-miss reporting
• Incorrect-blood-component-transfused errors
• Standardized case definitions
• National hemovigilance schemes (e.g., SHOT)
• International Haemovigilance Network
• Data-driven transfusion safety

Mechanisms

Hemovigilance systems gather standardized reports of transfusion-associated reactions and errors from hospitals and blood services, classify them using agreed case definitions and severity and imputability scales, and aggregate them at national and international levels. The resulting data reveal which hazards predominate, track trends over time, and allow the impact of interventions to be assessed. National schemes such as the UK Serious Hazards of Transfusion (SHOT) programme, described by Bolton-Maggs and Cohen, and international compilations such as the International Haemovigilance Network database analyzed by Politis and colleagues, illustrate how surveillance translates individual reports into population-level safety knowledge.

Clinical relevance

Hemovigilance underpins the evidence used to prioritize transfusion safety measures and to interpret the relative frequency and severity of the reactions described in the sibling topics of this area. This entry describes the surveillance framework for reference; it does not constitute operational reporting procedures or institutional policy.

Epidemiology

Hemovigilance data have documented the shift from infectious to non-infectious hazards as the dominant transfusion risks and have repeatedly identified TRALI, TACO, hemolytic reactions, and incorrect-blood-component-transfused errors among the most serious events. Politis and colleagues report patterns from the International Haemovigilance Network database, and Bolton-Maggs and Cohen summarize the UK experience; Vamvakas and Blajchman place these surveillance findings in the context of transfusion-related mortality.

History

Organized hemovigilance emerged in the 1990s, with France establishing an early national system and the United Kingdom launching the voluntary SHOT scheme in 1996. These efforts were later complemented by international coordination through the International Haemovigilance Network and, in the European Union, by directives mandating traceability and serious-adverse-reaction reporting, establishing hemovigilance as a standard component of blood-safety systems.

Seminal works

• bolton-maggs-2013
• politis-2022

Frequently asked questions

What is hemovigilance?

It is the systematic surveillance of adverse events and reactions across the whole transfusion chain, from donor to recipient, used to detect, analyze, and prevent transfusion-related harm — analogous to pharmacovigilance for medicines.

What has hemovigilance revealed about transfusion risk?

Aggregated hemovigilance data show that, with infectious risks now largely controlled, the leading serious hazards are non-infectious — including TRALI, TACO, hemolytic reactions, and errors that lead to transfusion of an incorrect blood component.